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Asymptomatic Profound Sinus Bradycardia (Heart
Rate 45) in Non-small Cell Lung Cancer Patients Treated
with Crizotinib
Sai-Hong Ignatius Ou, MD, PhD,* Michele Azada, MPH, BSc,* Joni Dy, RN, OCN,*
and Jonathan A. Stiber, MD†
Abstract: Crizotinib, a dual MET/ALK inhibitor, is now in ad-
vanced clinical development for the treatment of anaplastic lym-
phoma kinase (ALK)-rearranged non-small cell lung cancer
(NSCLC). We have observed several patients who developed pro-
found but asymptomatic sinus bradycardia (HR 45) during the
course of crizotinib treatment. Herein, we describe the clinical
characteristics of three separate patients enrolled in the A8081001
trial (NCT00585195) who developed asymptomatic profound sinus
bradycardia with their accompanying electrocardiogram tracings.
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Crizotinib is a dual MET/ALK inhibitor that is now inadvanced clinical trial in anaplastic lymphoma kinase
(ALK)-rearranged non-small cell lung cancer (NSCLC) pa-
tients. Preliminary results of crizotinib in 82 ALK-rearranged
NSCLC patients have been published.1 Crizotinib is generally
very well tolerated with mild grade 1 to 2 gastrointestinal
disturbances, grade 1 transient peripheral visual disturbances,
rare incidences of elevated liver function tests, and even rarer
cases of pneumonitis.1 We also observed that one of the
important pharmacodynamic effects of crizotinib in NSCLC
patients enrolled in the same trial (NCT00585195) that has
not been fully described yet is asymptomatic profound sinus
bradycardia (heart rate [HR] 45). Herein, we describe the
characteristics of three such patients with their accompanying
electrocardiograms (ECGs).
Case 1 is a 32-year-old Chinese female never-smoker
with stage IV ALK-rearranged NSCLC.2 She started on cr-
izotinib 250 mg orally twice a day as her fourth-line treatment
in early May 2010 with a pretreatment baseline HR of 84 by
ECG. Within 2 weeks of starting crizotinib, she developed
asymptomatic profound sinus bradycardia (HR 45) and
persisted throughout her crizotinib treatment (Figure 1).
There was no QTc prolongation on ECG, no electrolyte
abnormalities, and she had not been on any beta-blockers or
calcium channel blockers. Coincidentally, she achieved sig-
nificant tumor response by computed tomography/positron
emission tomography within 2 weeks and achieved partial
response by week 4 of crizotinib treatment. She remained
asymptomatic with normal blood pressure throughout her
entire course of crizotinib treatment without any dose reduc-
tion or delay until November 2010 when she developed
disease progression.
Case 2 is an 80-year-old Caucasian female with stage
IV de novo MET-amplified NSCLC with a former 45 pack-
year smoking history.3 Her pretreatment baseline ECG re-
vealed a HR of 71 and a PR interval of 209 milliseconds. She
started on crizotinib 250 mg orally twice a day as her
second-line treatment in late May 2010 with a day 1 ECG
revealing HR of 67 and a PR interval of 230 milliseconds.
She achieved rapid symptomatic and radiographic response to
crizotinib and a confirmed partial response within 4 weeks.
Simultaneously, serial ECGs as required by the protocol
revealed sinus bradycardia (HR 55) (HRs in the range of
48–51 and PR intervals of 211–217 milliseconds). She main-
tained the partial response on crizotinib, and by June 2011,
her HRs recorded at follow-up clinic visits revealed profound
sinus bradycardia (HR 45) (Figure 2). She remained
asymptomatic and there were no electrolyte abnormalities
and a normal thyroid panel. She had not been on any con-
current beta-blockers or calcium channel blockers. She con-
tinued to be on crizotinib at the same dose of 250 mg orally
twice a day for the past 14 months without any dose reduction
or delay as of her last follow-up on July 20, 2011.
Case 3 is a 50-year-old Mexican male former light
smoker (3 pack-year and quit 30 years ago) who was diag-
nosed with stage IV NSCLC in mid-2006. He started on
crizotinib 250 mg orally twice a day as his fourth-line
treatment in mid-August 2010 with a pretreatment baseline
*Chao Family Comprehensive Cancer Center, University of California Irvine
Medical Center, Orange, California; and †Division of Cardiology, De-
partment of Medicine, Duke University Medical Center, Durham, North
Carolina.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Sai-Hong Ignatius Ou, MD, PhD, Chao Family
Comprehensive Cancer Center, Division of Hematology/Oncology, De-
partment of Internal Medicine, University of California Irvine Medical
Center, 101 The City Drive, Bldg 56, RT 81, Rm 241, Orange, CA
92868-3298. E-mail: Ignatius.ou@uci.edu
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0612-2135
Journal of Thoracic Oncology • Volume 6, Number 12, December 2011 2135
HR of 65 by ECG. Serial ECGs on day 1 of crizotinib
revealed HRs between 54 and 62. Two weeks later, serial
ECGs revealed that he has developed sinus bradycardia (HRs
51–54). By March 2011, he has developed profound sinus
bradycardia (HR 45) but remained asymptomatic and con-
tinued to exercise on a treadmill everyday. ECG recorded his
HR to be 39 on a clinic visit in July 2011 (Figure 3). He
exercised regularly and his performance status has remained
at 0 throughout the 12 months of crizotinib treatment. Again,
there were no electrolyte abnormalities with a normal thyroid
panel nor was he on any beta-blocker or calcium channel
blockers. His blood pressure remained normal throughout his
crizotinib treatment. He continued to have confirmed partial
response on crizotinib without any dose reduction or delay as
of his last follow-up on July 20, 2011.
DISCUSSION
Sinus bradycardia has never been associated with
small-molecule receptor tyrosine kinase inhibitors currently
being used in cancer therapy.4 The three patients described
here varied in age, gender, ethnicity, smoking status, line of
treatment, and time to profound sinus bradycardia. Crizotinib
is a small-molecule multitargeted receptor tyrosine kinase
inhibitor, and the profound sinus bradycardia observed in
some patients is likely due to its dose-dependent pharmaco-
dynamic effects.5 To date, we have observed eight patients
who have developed asymptomatic sinus bradycardia out of
39 ALK-rearranged and 1 MET-amplified NSCLC patients
enrolled in NCT00585195. All eight patients maintained a
normal blood pressure throughout their crizotinib treatment.
FIGURE 1. A 32-year-old with si-
nus bradycardia (HR  43), PR in-
terval of 130 milli-second (ms), and
QTc  439 milliseconds after 2
weeks of crizotinib treatment. Nor-
mal range for PR interval  120–
200 milliseconds, normal QTc
470 milliseconds.6
FIGURE 2. A 80-year-old with si-
nus bradycardia (HR  44), PR in-
terval of 229 milliseconds (base-
line), and QTc of 409 milliseconds
after 12 months of crizotinib treat-
ment. Normal range for PR inter-
val  120–200 milliseconds, nor-
mal QTc 470 milliseconds.6
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It will be important to report the incidence of profound sinus
bradycardia in the larger cohort of ALK-rearranged NSCLC
patients enrolled in NCT00585195, the characteristics of
these patients, the time to onset of profound sinus bradycar-
dia, and any correlation between profound sinus bradycardia
and response. It has been reported that there was an average
decrease in HR of 2.5 beats per minute per 100 ng/ml
increase in crizotinib concentration without any prolongation
of QTc.5 This dose-dependent and potential dosing-limiting
pharmacodynamic effect of crizotinib may be similar to the
skin rash observed in epidermal growth factor receptor ty-
rosine kinase inhibitors. Because the current Common Ter-
minology Criteria Adverse Event only grades sinus bradycar-
dia according to symptoms and whether intervention is
required and not by the actual HRs, profound sinus brady-
cardia as observed in our patients may not be easily noticed
within a large clinical trial, especially if they are asymptom-
atic. Finally, we continued crizotinib on all three patients
without dose reduction or delay as they were asymptomatic
and benefiting from continuous crizotinib treatment against a
deadly disease. We do leave clear instruction for our patients
to report any signs of sinus bradycardia such as dizziness or
syncope immediately.
Most ALK-rearranged NSCLC patients are younger and
have never smoked, thus having few if any comorbidities
and good performance statuses and can tolerate the profound
sinus bradycardia without symptoms. Nevertheless, it is im-
portant for the general oncology community to be aware of
this pharmacodynamic effect of crizotinib as patients can be
on crizotinib for a prolonged period of time, and that a
detailed review of symptoms and medications especially
beta-blockers and calcium channel blockers such as vera-
pamil and diltiazem is performed before and continuously
during crizotinib treatment.
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FIGURE 3. A 50-year-old with si-
nus bradycardia (HR  39), PR in-
terval of 174 milliseconds, and QTc
of 436 milliseconds after 11
months of crizotinib treatment.
Normal range for PR interval 
120–200 milliseconds, normal QTc
470 milliseconds.6
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